In the last trading session, 3.2 million shares of the Taysha Gene Therapies Inc (NASDAQ:TSHA) were traded, and its beta was 0.88. Most recently the company’s share price was $1.87, and it changed around $0.12 or 6.86% from the last close, which brings the market valuation of the company to $383.24M. TSHA currently trades at a discount to its 52-week high of $4.32, offering almost -131.02% off that amount. The share price’s 52-week low was $1.19, which indicates that the current value has risen by an impressive 36.36% since then. We note from Taysha Gene Therapies Inc’s average daily trading volume that its 10-day average is 2.32 million shares, with the 3-month average coming to 4.12 million.
Taysha Gene Therapies Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.09. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended TSHA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Taysha Gene Therapies Inc is expected to report earnings per share of 0 for the current quarter.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Instantly TSHA has showed a green trend with a performance of 6.86% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8800 on recent trading dayincreased the stock’s daily price by 0.53%. The company’s shares are currently up 8.09% year-to-date, but still up 22.22% over the last five days. On the other hand, Taysha Gene Therapies Inc (NASDAQ:TSHA) is -3.11% down in the 30-day period. We can see from the shorts that 23.95 million shares have been sold at a short interest cover period of 10.38 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 62.6% from its current value. Analyst projections state that TSHA is forecast to be at a low of $5 and a high of $5.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
The year-over-year growth rate is expected to be -46.63%, down from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 2.05M in revenue for the current quarter. 8 analysts expect Taysha Gene Therapies Inc to make 1.49M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.6M and 3.41M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -43.04%. Forecasts for the next quarter put sales growth at -56.25%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -137.69%. Taysha Gene Therapies Inc earnings are expected to increase by 61.44% in 2025, but the outlook is positive 30.94% per year for the next five years.
TSHA Dividends
Taysha Gene Therapies Inc’s next quarterly earnings report is expected to be released in March.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 18.34% of Taysha Gene Therapies Inc shares, and 77.22% of them are in the hands of institutional investors. The stock currently has a share float of 94.57%. Taysha Gene Therapies Inc stock is held by 158.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 9.1722% of the shares, which is about 21.21 million shares worth $47.51 million.
RTW INVESTMENTS, LP, with 8.1299% or 18.8 million shares worth $42.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF were the top two Mutual Funds as of Nov 30, 2024 . The former held 5.57 shares worth $10.42 million, making up 2.72% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 4.84 shares worth around $9.06 million, which represents about 2.36% of the total shares outstanding.
